Fikry Qadir

Prof. Fikry Qadir

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
DMDilshad Hussein Muhammad
Dilshad Hussein Muhammad
FQFikry Qadir
Fikry Qadir
The present study was carried out to show the effects of nightshift working on some immunological, serum cortisol level, and malondialdehyde (MDA) on male nurses in Hawler city hospitals. After performing the exclusion and inclusion criteria, ninety-six male nurses were participated in this study. According to working shifts, the participants were divided into two groups. First group includes sixty seven night-shift male nurses working for 3-12 years with 8-10 nights/month. The second group consisted of twenty-nine day-shift male nurses working for 3-12 years. The age range of both groups was (≥20-40≤). The second group was used as a control group for statistical comparison. The results showed that night-shift working in male nurses was associated with significant increases in tumor necrosis factor-α (TNF-α) (77.15 ± 3.328 vs.101.1 ± 6.968, p=0.024), interleukin-2 (IL-2) (1147 ± 59.54vs1626 ± 34.71, p=0.001), and interferon-γ (IFN-γ) (272.3 ± 16.00 vs. 319.6 ± 12.48, p=0.029) when compared with day-shift group. Two-fold significant increase of high-sensitive C-reactive protein (hs-CRP) (3154 ± 403.3 vs. 6739 ± 334.0, p=0.001) was found in nightshift group as compared with day-shift group. Prostate specific antigen (PSA) estimation showed no significant increase in night-shift group in comparison with day-shift group (1.755 ± 0.202 vs. 1.987 ± 0.159, p=0.424). The results also showed that night-shift working was associated with significant elevations in serum cortisol levels when compared with dayshift nurses (7.844 ± 0.529 vs. 11.18 ± 0.406, p=0.001). Similar significant increasing was also observed for serum malondialdehyde (MDA) (1.124 ± 0.075 vs. 1.681 ± 0.079, p=0.001) in night-shift group when compared with day-shift group.

27 May 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
SMSarbaz Ibrahim Mohammed
Sarbaz Ibrahim Mohammed
KHKawa Muhamed-Amin Hassan
Kawa Muhamed-Amin Hassan
DADarya Mohammed Azeez
Darya Mohammed Azeez
FQFikry Qadir
Fikry Qadir
Abbas SalihiAbbas Salihi
Abbas Salihi
The present study investigated the relationship between single nucleotide polymorphisms in the interleukin (IL)-15 gene located (exon 8) on the chromosomal location 4q31.21 and acute lymphoblastic leukaemia (ALL) risk in Iraqi patients. A total of 78 (49 male -29 female) primary ALL (62B-cell, 16 T-cells lineages cases and 30 healthy control subjects (median age 11, age range were 4-21.5), were enrolled at the Nanakaly Hospital of Erbil Province between February 2021 and January 2022. The genotype analysis was performed using polymerase chain reaction (PCR) and Sanger DNA sequencing. The IL15 homozygous rs10833 (100%) and rs2291596 (63.6%) genotypes indicated high frequencies and were associated with a risk of developing ALL, while the remaining 16 novel mutations indicated in low frequency (9.1%) except for the 97270G>GT genotype (18.2%). High expression levels were noted for different clusters of differentiation (CD) biomarkers between both subtypes of ALL, including, CD10, CD19, CD22, CD79a, CD99, terminal deoxynucleotidyl transferase (TdT), and human leukocyte antigen DR (HLA-DR) isotype in B-cells lineages, while, CD2, CD3, CD5, CD7, CD13, CD117 and TdT are more specific to T-cells lineages. On the other hand, significant changes were noted in certain hematological parameters including red blood cells (RBCs), haemoglobin (g/dl), haematocrite (HCt %), red blood cell distribution width (RDW %), and platelet counts (PLT- 109/L) compared with those of healthy subjects. Finally, it was concluded that various novel mutations were recorded with different subtypes of ALL diseases, and mild anemia was observed among patients. Future studies will be towered to associate these mutations with prognosis and therapeutic response of diseases.

20 January 2026 in ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY
Verified
Journal Article
Open access
JSJutyar I. Saber
Jutyar I. Saber
HFHiwa R. Fatah
Hiwa R. Fatah
FQFikry Qadir
Fikry Qadir
Globally, prostate cancer (PCa) is becoming more prevalent and lethal. The progression of PCa is linked to both inflammation and angiogenesis. Pro-inflammatory cytokines, interleukin (IL)-8) and vascular endothelial growth factor (VEGF), promote inflammation, angiogenesis, and PCa progression. On the other hand, IL-27 (IL-27) has antitumor effects, modulates immune system activity, and thus serves as a suppressor of tumor growth. In the Kurdistan Region of Iraq, there is limited evidence linking these cytokines and their gene polymorphisms to PCa. This case–control study included 50 PCa patients and 30 age-matched healthy controls. Serum levels of these three cytokines were evaluated by enzyme-linked immunosorbent assay, whereas PCR and Sanger sequencing were used to find polymorphisms in IL-8 (rs4073, rs2227306), IL-27 (rs153109), and VEGF (rs2010963) in formalin-fixed paraffinembedded tissue DNA. GeneMANIA was used to assess gene-gene interaction networks. Statistical analyses were performed using Mann–Whitney U tests. Patients with PCa showed elevated IL-8 and VEGF levels and reduced IL-27 levels compared to controls (p < 0.05). Multiple single-nucleotide polymorphisms were found in all target genes, several of which were new to the GenBank. Gene-network analysis revealed that these three cytokines are involved in shared inflammatory, immunomodulatory, and angiogenic pathways. This study shows that altered serum levels and gene polymorphisms of these three cytokines may be biomarkers for PCa diagnosis and progression. It underlines the molecular interplay between inflammatory and angiogenic mediators and supports further cytokine-based diagnostic and therapeutic research.

12 May 2026 in Immuno
Verified
Journal Article
Open access
PDF file
SSshukur smail
shukur smail
AFAbdullah Hayder Flaih
Abdullah Hayder Flaih
BIBlnd Ismail
Blnd Ismail
AAAkhter Ahmed Ahmed
Akhter Ahmed Ahmed
ABAhmed Abdulrazzaq Bapir
Ahmed Abdulrazzaq Bapir
Christer JansonChrister Janson
Christer Janson
Living therapies, including chimeric antigen receptor T (CAR-T) cells, oncolytic viruses (OVs), and bacteria-based platforms, are emerging as promising approaches in cancer treatment because they can directly target tumors and modulate anti-tumor immunity. This narrative review summarizes current knowledge on these therapies, focusing on their mechanisms of action, therapeutic applications, major limitations, and recent advances in genetic engineering, synthetic biology, and delivery systems. CAR-T cell therapy has shown substantial clinical success in hematological malignancies through the genetic redirection of T cells against tumor-associated antigens, although its efficacy in solid tumors remains limited by antigen heterogeneity and the immunosuppressive tumor microenvironment (TME). OVs selectively infect and lyse malignant cells while also stimulating local and systemic immune responses, and engineered OVs may further enhance therapeutic activity by reshaping the TME. Bacteria-based therapies exploit the natural tumor-targeting ability of selected strains, particularly in hypoxic regions, to deliver therapeutic agents and activate immune responses. Despite encouraging progress, safety concerns, immune-related barriers, and tumor complexity remain major challenges. Overall, integrating living therapies with modern biotechnological advances and existing treatment modalities may support more personalized and synergistic strategies for cancer management.